Status:
UNKNOWN
Mesoglycan for Acute Hemorrhoidal Disease
Lead Sponsor:
Societa Italiana di Chirurgia ColoRettale
Collaborating Sponsors:
Neopharmed Gentili S.p.A.
Conditions:
Hemorrhoids
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Hemorrhoidal disease (HD) is the most common proctological disease with a prevalence rate that can reach approximately 4.4% of the population, with a particular peak in individuals aged between 45 and...
Eligibility Criteria
Inclusion
- Diagnosis of grade I-III hemorrhoidal disease classified according to Goligher classification or diagnosis of external hemorrhoid thrombosis
- Female patients of childbearing age with a negative pregnancy test
- Patients able to understand informed consent
- Signed Informed Consent.
Exclusion
- Blood coagulations disorders
- Patients undergoing chemoradiation
- intake of anticoagulants
- pregnancy
Key Trial Info
Start Date :
January 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06101992
Start Date
January 1 2024
End Date
September 1 2024
Last Update
October 31 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.